Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Mugs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Oct 03, 2021 9:42pm
146 Views
Post# 33959476

RE:Mugs

RE:MugsAs I said in 2014 - I've stayed true to my conviction and continue to accumulate.
One just needs to watch the Goodman video from 2014 to understand what he's asking of shareholders - to be patient - as he needs 10 years to build it.
We are almost finished 7 years and sales have gone from zero to 200 million per year.

Not sure why any of that is a crime but if you don't like it, you don't need to invest in it.

I provide data and links as information becomes available.
The latest link was regarding Raymond James "outperform 2" rating.

https://www.cantechletter.com/2021/09/knight-therapeutics-strengthens-its-portfolio-raymond-james-says/

Everytime we provide information, you guys take offense.
I don't understand - but - please be open-minded to our discussions here.
We have every right to discuss the company.
If you're not interested, there are other stocks for you to follow.

Thanks.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities